Article 77. Pharmacovigilance
Law 105/2016/QH13 — Luật Dược số 105/2016/QH13
Drug information, pharmacovigilance and
1. Pharmacovigilance activities include:
a/ Monitoring, detecting and reporting on information relating to adverse reactions of drugs, errors related to drugs, or suspicious counterfeit drugs or substandard drugs, and information relating to drugs having no treatment effects or failing to produce desirable treatment effects;
b/ Collecting and processing information mentioned at Point a of this Clause; evaluating benefits and risks, making conclusions and managing risks related to drugs;
c/ Announcing competent agencies’ conclusions on drug safety issues.
2. When detecting abnormal signs in the course of using a drug, the user shall notify them to the person who has provided medical examination and treatment or to the drug retailing establishment where he/she has bought the drug, and come to a medical examination and treatment establishment for timely treatment.
3. A medicine practitioner has the following responsibilities:
a/ To proactively monitor and detect abnormal signs or errors related to drugs or suspicious quality or effects of drugs in the course of practice;
b/ To evaluate, handle and take preventive measures when detecting any abnormal signs or errors or when receiving information from drug users as prescribed in Clause 2 of this Article;
c/ To report to competent agencies on information collected when performing the responsibilities prescribed at Points a and b of this Clause.
4. A drug retailer has the following responsibilities:
a/ To provide drug users with counseling within its professional scope on actions to be taken when detecting abnormal signs during the use of a drug;
b/ To collect, and report to competent agencies on, information on abnormal signs during the use of drugs.
5. A drug manufacture establishment, drug preparation and processing establishment, or drug registration establishment has the following responsibilities:
a/ To monitor the quality, safety and efficacy of drugs circulated in the market;
b/ To report and update information to competent agencies on the quality, safety and efficacy of drugs it has manufactured, registered, prepared or processed.
6. The Minister of Health shall prescribe the suspension of the manufacture, trading, use, sealing and storage of drugs that show unsafe signs for users.
Article 77, Law 105/2016/QH13